M

Mersana Therapeutics
D

MRSN

6.88000
USD
6.57
(2,126.54%)
مغلق
حجم التداول
6,168
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
857,463,612
أصول ذات صلة
AMGN
AMGN
-5.44
(-1.77%)
301.22 USD
C
CRSP
-1.010
(-1.56%)
63.750 USD
E
EDIT
-0.18000
(-5.73%)
2.96000 USD
INCY
INCY
0.030
(0.04%)
70.210 USD
N
NKTR
-1.370
(-5.48%)
23.650 USD
REGN
REGN
-4.60
(-0.82%)
558.62 USD
المزيد
الأخبار المقالات

العنوان: Mersana Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.